Label: CEFPROZIL tablet, film coated
CEFPROZIL tablet, film coated

  • NDC Code(s): 64679-712-01, 64679-712-02, 64679-712-03, 64679-712-04, view more
    64679-713-01, 64679-713-02, 64679-713-03
  • Packager: Wockhardt USA LLC.
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated May 7, 2018

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED SECTION

    Rx Only

    To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil tablets and other antibacterial drugs, cefprozil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

  • DESCRIPTION

    Cefprozil is a semi-synthetic broad-spectrum cephalosporin antibiotic. Cefprozil is a cis and trans isomeric mixture (≥90% cis). The chemical name for the monohydrate is (6R, 7R)-7-[(R)-2-Amino-2-(p-hydroxyphenyl) acetamido]-8- oxo-3-propenyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monohydrate, and the structural formula is:

    Structure

    Cefprozil is a white to yellowish powder with a molecular formula for the monohydrate of C18H19N3O5S•H2O and a molecular weight of 407.45.

    Cefprozil tablets are intended for oral administration.

    Cefprozil tablets contain cefprozil equivalent to 250 mg or 500 mg of anhydrous cefprozil. In addition, each tablet contains the following inactive ingredients: microcrystalline cellulose, methylcellulose, sodium starch glycolate, low substituted hydroxypropyl cellulose, magnesium stearate, polyethylene glycol, hypromellose, and titanium dioxide.

  • CLINICAL PHARMACOLOGY

    The pharmacokinetic data were derived from the capsule formulation; however, bioequivalence has been demonstrated for the oral solution, capsule, tablet, and suspension formulations under fasting conditions.

    Following oral administration of cefprozil to fasting subjects, approximately 95% of the dose was absorbed. The average plasma half-life in normal subjects was 1.3 hours, while the steady-state volume of distribution was estimated to be 0.23 L/kg. The total body clearance and renal clearance rates were approximately 3 mL/min/kg and 2.3 mL/min/kg, respectively.

    Average peak plasma concentrations after administration of 250 mg, 500 mg, or 1 g doses of cefprozil to fasting subjects were approximately 6.1, 10.5, and 18.3 mcg/mL, respectively, and were obtained within 1.5 hours after dosing. Urinary recovery accounted for approximately 60% of the administered dose. (See Table.)

    *Data represent mean values of 12 healthy volunteers.

    Dosage
    Mean Plasma Cefprozil
    8-hour Urinary Excretion
    (mg)
    Concentrations (mcg/mL)*
    (%)
    Peak appx. 1.5 h
    4h
    8h
    250 mg
    6.1
    1.7
    0.2
    60%
    500 mg
    10.5
    3.2
    0.4
    62%
    1000 mg
    18.3
    8.4
    1.0
    54%

    During the first 4-hour period after drug administration, the average urine concentrations following 250 mg, 500 mg, and 1 g doses were approximately 700 mcg/mL, 1000 mcg/mL, and 2900 mcg/mL, respectively.

    Administration of Cefprozil tablet formulation with food did not affect the extent of absorption (AUC) or the peak plasma concentration (Cmax) of cefprozil. However, there was an increase of 0.25 to 0.75 hours in the time to maximum plasma concentration of cefprozil (Tmax).

    The bioavailability of the capsule formulation of cefprozil was not affected when administered 5 minutes following an antacid.

    Plasma protein binding is approximately 36% and is independent of concentration in the range of 2 mcg/mL to 20 mcg/mL.

    There was no evidence of accumulation of cefprozil in the plasma in individuals with normal renal function following multiple oral doses of up to 1000 mg every 8 hours for 10 days.

    In patients with reduced renal function, the plasma half-life may be prolonged up to 5.2 hours depending on the degree of the renal dysfunction. In patients with complete absence of renal function, the plasma half-life of cefprozil has been shown to be as long as 5.9 hours. The half-life is shortened during hemodialysis. Excretion pathways in patients with markedly impaired renal function have not been determined. (See PRECAUTIONS and DOSAGE AND ADMINISTRATION.)

    In patients with impaired hepatic function, the half-life increases to approximately 2 hours. The magnitude of the changes does not warrant a dosage adjustment for patients with impaired hepatic function.

    Healthy geriatric volunteers (≥65 years old) who received a single 1-g dose of cefprozil had 35% to 60% higher AUC and 40% lower renal clearance values compared with healthy adult volunteers 20 to 40 years of age. The average AUC in young and elderly female subjects was approximately 15 to 20% higher than in young and elderly male subjects. The magnitude of these age- and gender-related changes in the pharmacokinetics of cefprozil is not sufficient to necessitate dosage adjustments.

    Adequate data on CSF levels of cefprozil are not available.

    Comparable pharmacokinetic parameters of cefprozil are observed between pediatric patients (6 months to 12 years) and adults following oral administration of selected matched doses. The maximum concentrations are achieved at 1 to 2 hours after dosing. The plasma elimination half-life is approximately 1.5 hours. In general, the observed plasma concentrations of cefprozil in pediatric patients at the 7.5, 15, and 30 mg/kg doses are similar to those observed within the same time frame in normal adult subjects at the 250, 500, and 1000 mg doses, respectively. The comparative plasma concentrations of cefprozil in pediatric patients and adult subjects at the equivalent dose level are presented in the table below.

    an=11; bn=5; cn=9; dn=11

    Mean (SD) Plasma Cefprozil Concentrations (mcg/mL)
    Population
    Dose
    1 h
    2 h
    4 h
    6h
    T½ (h)
    children
    7.5 mg/kg
    4.70
    3.99
    0.91
    0.23a
    0.94
    (n=18)
    (1.57)
    ( 1.24)
    (0.30)
    (0.13)
    (0.32)
    adults
    250 mg
    4.82
    4.92
    1.70b
    0.53
    1.28
     (n=12)
    (2.13)
    (1.13)
    (0.53)
    (0.17)
    (0.34)
    children
    15 mg/kg
    10.86
    8.47
    2.75
    0.61c
    1.24
    (n=19)
    (2.55)
    (2.03)
    (1.07)
    (0.27)
    (0.43)
    adults
    500 mg
    8.39
    9.42
    3.18d
    1.00d
    1.29
    (n=12)
    (1.95)
    (0.98)
    (0.76)
    (0.24)
    (0.14)
    children
    30 mg/kg
    16.69
    17.61
    8.66
    --
    2.06
    (n=10)
    (4.26)
    (6.39)
    (2.70)
    (0.21)
    adults
    1000 mg
    11.99
    16.95
    8.36
    2.79
    1.27
    (n=12)
    (4.67)
    (4.07)
    (4.13)
    (1.77)
    (0.12)

    Microbiology

    Cefprozil has in vitro activity against a broad range of gram-positive and gram-negative bacteria. The bactericidal action of cefprozil results from inhibition of cell-wall synthesis. Cefprozil has been shown to be active against most strains of the following microorganisms both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section.

    Aerobic gram-positive
    microorganisms:
    Aerobic gram-negative
    microorganisms:
    Staphylococcus aureus (including
    β-lactamase- producing strains)
    Haemophilus influenzae (including β–lactamase-producing
    strains)
    NOTE: Cefprozil is inactive against methicillin-resistant staphylococci.
    Streptococcus pneumoniae
    Streptococcus pyogenes
    Moraxella (Branhamella)
    catarrhalis (including β–lactamase-producing strains)

    The following in vitro data are available; however, their clinical significance is unknown. Cefprozil exhibits in vitro minimum inhibitory concentrations (MICs) of 8 mcg/mL or less against most (≥90%) strains of the following microorganisms; however, the safety and effectiveness of cefprozil in treating clinical infections due to these microorganisms have not been established in adequate and well-controlled clinical trials.

    Aerobic gram-positive microorganisms:

                NOTE: Cefprozil is inactive against Enterococcus faecium .

    Enterococcus durans
    Staphylococcus warneri
    Enterococcus faecalis
    Streptococcus agalactiae
    Listeria monocytogenes
    Streptococci (Groups C,D,F, and G)
    Staphylococcus epidermidis
    viridans group Streptococci
    Staphylococcus saprophyticus

    Aerobic gram-negative microorganisms:

                NOTE: Cefprozil is inactive against most strains of Acinetobacter, Enterobacter,   Morganella morganii, Proteus vulgaris, Providencia, Pseudomonas, and Serratia.

    Citrobacter diversus
    Proteus mirabilis
    Escherichia coli
    Salmonella spp.
    Klebsiella pneumoniae
    Shigella spp.
    Neisseria gonorrhoeae
    Vibrio spp.
    (including β-lactamase-producing strains)

    Anaerobic microorganisms:

                NOTE: Most strains of the Bacteroides fragilis group are resistant to cefprozil.

    Prevotella (Bacteroides) melaninogenicus
    Fusobacterium spp.
    Clostridium difficile
    Peptostreptococcus spp.
    Clostridium perfringens
    Propionibacterium acnes

    Susceptibility Tests

    For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.

  • INDICATIONS AND USAGE

    Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below:

    UPPER RESPIRATORY TRACT

    Pharyngitis/tonsillitis caused by Streptococcus pyogenes.

    NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present.

    Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella  (Branhamella) catarrhalis (including β-lactamase-producing strains). (See CLINICAL STUDIES.)

    NOTE: In the treatment of otitis media due to β-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those  observed with a product containing a specific β-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing β-lactamase inhibitors.

    Acute Sinusitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including β-lactamase-producing strains).

    LOWER RESPIRATORY TRACT

    Acute Bacterial Exacerbation of Chronic Bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including β-lactamase-producing strains).

    SKIN AND SKIN STRUCTURE

    Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including penicillinase-producing strains) and Streptococcus pyogenes. Abscesses usually require surgical drainage.

    To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil tablets and other antibacterial drugs, cefprozil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

  • CONTRAINDICATIONS

    Cefprozil is contraindicated in patients with known allergy to the cephalosporin class of antibiotics.

  • WARNINGS

    BEFORE THERAPY WITH CEFPROZIL IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEFPROZIL, CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF THIS PRODUCT IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS-SENSITIVITY AMONG β-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY. IF AN ALLERGIC REACTION TO CEFPROZIL OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED.

    Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including cefprozil, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

    C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin-producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

    If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

  • PRECAUTIONS

    General

    Prescribing cefprozil in the absence of proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

    In patients with known or suspected renal impairment (see DOSAGE AND ADMINISTRATION), careful clinical observation and appropriate laboratory studies should be done prior to and during therapy. The total daily dose of cefprozil should be reduced in these patients because high and/or prolonged plasma antibiotic concentrations can occur in such individuals from usual doses. Cephalosporins, including cefprozil, should be given with caution to patients receiving concurrent treatment with potent diuretics since these agents are suspected of adversely affecting renal function.

    Prolonged use of cefprozil may result in the overgrowth of nonsusceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.

    Cefprozil should be prescribed with caution in individuals with a history of gastrointestinal disease particularly colitis.

    Positive direct Coombs' tests have been reported during treatment with cephalosporin antibiotics.

    Information for Patients

    Patients should be counseled that antibacterial drugs including cefprozil should only be used to treat bacterial infections. They do not treat viral infections (eg, the common cold). When cefprozil is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by cefprozil or other antibacterial drugs in the future.

    Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.

    Drug Interactions

    Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporin antibiotics. Concomitant administration of probenecid doubled the AUC for cefprozil.

    The bioavailability of the capsule formulation of cefprozil was not affected when administered 5 minutes following an antacid.

    Drug/laboratory Test Interactions

    Cephalosporin antibiotics may produce a false positive reaction for glucose in the urine with copper reduction tests (Benedict's or Fehling's solution or with Clinitest® tablets1), but not with enzyme-based tests for glycosuria (e.g., Clinistix®). A false negative reaction may occur in the ferricyanide test for blood glucose. The presence of cefprozil in the blood does not interfere with the assay of plasma or urine creatinine by the alkaline picrate method.

    ___________________________________

    1 Clinitest® and Clinistix® are registered trademarks of Bayer Healthcare LLC.

    Carcinogenesis, Mutagenesis, Impairment of Fertility

    Long term in vivo studies have not been performed to evaluate the carcinogenic potential of cefprozil.

    Cefprozil was not found to be mutagenic in either the Ames Salmonella or E. coli WP2 urvA reversion assays or the Chinese hamster ovary cell HGPRT forward gene mutation assay and it did not induce chromosomal abnormalities in Chinese hamster ovary cells or unscheduled DNA synthesis in rat hepatocytes in  vitro. Chromosomal aberrations were not observed in bone marrow cells from rats dosed orally with over 30 times the highest recommended human dose based upon mg/m2.

    Impairment of fertility was not observed in male or female rats given oral doses of cefprozil up to 18.5 times the highest recommended human dose based upon mg/m2.

    Pregnancy

    Teratogenic Effects. Pregnancy Category B

    Reproduction studies have been performed in rabbits, mice, and rats using oral doses of cefprozil of 0.8, 8.5, and 18.5 times the maximum daily human dose (1000 mg) based upon mg/m2, and have revealed no harm to the fetus. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

    Labor and Delivery

    Cefprozil has not been studied for use during labor and delivery. Treatment should only be given if clearly needed.

    Nursing Mothers

    Small amounts of cefprozil (<0.3% of dose) have been detected in human milk following administration of a single 1 gram dose to lactating women. The average levels over 24 hours ranged from 0.25 to 3.3 mcg/mL. Caution should be exercised when cefprozil is administered to a nursing woman, since the effect of cefprozil on nursing infants is unknown.

    Pediatric Use

    (See INDICATIONS AND USAGE and DOSAGE AND ADMINISTRATION.)

    The safety and effectiveness of cefprozil in the treatment of otitis media have been established in the age groups 6 months to 12 years. Use of cefprozil for the treatment of otitis media is supported by evidence from adequate and well-controlled studies of cefprozil in pediatric patients. (See CLINICAL STUDIES.)

    The safety and effectiveness of cefprozil in the treatment of pharyngitis/tonsillitis or uncomplicated skin and skin-structure infections have been established in the age groups 2 to 12 years. Use of cefprozil for the treatment of these infections is supported by evidence from adequate and well-controlled studies of cefprozil in pediatric patients.

    The safety and effectiveness of cefprozil in the treatment of acute sinusitis have been established in the age groups 6 months to 12 years. Use of cefprozil in these age groups is supported by evidence from adequate and well-controlled studies of cefprozil in adults.

    Safety and effectiveness in pediatric patients below the age of 6 months have not been established for the treatment of otitis media or acute sinusitis, or below the age of 2 years for the treatment of pharyngitis/tonsillitis or uncomplicated skin and skin-structure infections. However, accumulation of other cephalosporin antibiotics in newborn infants (resulting from prolonged drug half-life in this age group) has been reported.

    Geriatric Use

    Of the more than 4500 adults treated with cefprozil in clinical studies, 14% were 65 years and older, while 5% were 75 years and older. When geriatric patients received the usual recommended adult doses, their clinical efficacy and safety were comparable to clinical efficacy and safety in nongeriatric adult patients. Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals to the effects of cefprozil cannot be excluded (see CLINICAL PHARMACOLOGY).

    Cefprozil is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function. See DOSAGE AND ADMINISTRATION for dosing recommendations for patients with impaired renal function.

  • ADVERSE REACTIONS

    The adverse reactions to cefprozil are similar to those observed with other orally administered cephalosporins. Cefprozil was usually well tolerated in controlled clinical trials. Approximately 2% of patients discontinued cefprozil therapy due to adverse events.

    The most common adverse effects observed in patients treated with cefprozil are:

    Gastrointestinal: Diarrhea (2.9%), nausea (3.5%), vomiting (1%), and abdominal pain (1%).

    Hepatobiliary: Elevations of AST (SGOT) (2%), ALT (SGPT) (2%), alkaline phosphatase (0.2%), and bilirubin values (<0.1%). As with some penicillins and some other cephalosporin antibiotics, cholestatic jaundice has been reported rarely.

    Hypersensitivity: Rash (0.9%), urticaria (0.1%). Such reactions have been reported more frequently in children than in adults. Signs and symptoms usually occur a few days after initiation of therapy and subside within a few days after cessation of therapy.

    CNS: Dizziness (1%), hyperactivity, headache, nervousness, insomnia, confusion, and somnolence have been reported rarely (<1%). All were reversible.

    Hematopoietic: Decreased leukocyte count (0.2%), eosinophilia (2.3%).

    Renal: Elevated BUN (0.1%), serum creatinine (0.1%).

    Other: Diaper rash and superinfection (1.5%), genital pruritus and vaginitis (1.6%).

    The following adverse events, regardless of established causal relationship to cefprozil, have been rarely reported during postmarketing surveillance: anaphylaxis, angioedema, colitis (including pseudomembranous colitis), erythema multiforme, fever, serumsickness like reactions, Stevens-Johnson syndrome, and thrombocytopenia.

    Cephalosporin class paragraph

    In addition to the adverse reactions listed above which have been observed in patients treated with cefprozil, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibiotics:

    Aplastic anemia, hemolytic anemia, hemorrhage, renal dysfunction, toxic epidermal necrolysis, toxic nephropathy, prolonged prothrombin time, positive Coomb's test, elevated LDH, pancytopenia, neutropenia, agranulocytosis.

    Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment, when the dosage was not reduced. (See DOSAGE AND ADMINISTRATION and OVERDOSAGE.) If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.

  • OVERDOSAGE

    Single 5000 mg/kg oral doses of cefprozil caused no mortality or signs of toxicity in adult, weanling, or neonatal rats, or adult mice. A single oral dose of 3000 mg/kg caused diarrhea and loss of appetite in cynomolgus monkeys, but no mortality.

    Cefprozil is eliminated primarily by the kidneys. In case of severe overdosage, especially in patients with compromised renal function, hemodialysis will aid in the removal of cefprozil from the body.

  • DOSAGE AND ADMINISTRATION

    Cefprozil tablets are administered orally.

    a In the treatment of infections due to Streptococcus pyogenes , Cefprozil tablets should be administered for at least 10 days.

    b Not to exceed recommended adult doses.

    Population/Infection
    Dosage
    (mg)
    Duration (days)
    ADULTS (13 years and older)
         UPPER RESPIRATORY TRACT
                Pharyngitis/Tonsillitis
    500 q24h
    10a
                Acute Sinusitis
                (For moderate to severe infections, the higher dose should be       used)
    250 q12h or
    500 q12h
    10
         LOWER RESPIRATORY TRACT
                  Acute Bacterial Exacerbation of Chronic Bronchitis
    500 q12h
    10
                  SKIN AND SKIN STRUCTURE
                  Uncomplicated Skin and Skin Structure Infections
    250 q12h or
    500 q24h or
    500 q12h
    10
    CHILDREN (2 years to 12 years)
         UPPER RESPIRATORY TRACTb
                  Pharyngitis/Tonsillitis
    7.5 mg/kg q12h
    10a
         SKIN AND SKIN STRUCTURE
                  Uncomplicated Skin and Skin  Structure Infections
    20 mg/kg q24h
    10
    INFANTS & CHILDREN (6 months to12 years)
         UPPER RESPIRATORY TRACTb
                  Otitis Media (See INDICATIONS AND USAGE and
                  CLINICAL STUDIES )
    15 mg/kg q12h
    10
                  Acute Sinusitis
                  (For moderate to severe infections, the higher dose should           be used)
    7.5 mg/kg q12h or
    15 mg/kg q12h
    10

    Renal Impairment

    Cefprozil may be administered to patients with impaired renal function. The following dosage schedule should be used.

    *Cefprozil is in part removed by hemodialysis; therefore, cefprozil should be administered after the completion of hemodialysis.

    Creatinine Clearance
    (mL/min)
    Dosage
    (mg)
    Dosing Interval
    30-120
    standard
    standard
    0-29*
    50% of standard
    standard

    Hepatic Impairment

    No dosage adjustment is necessary for patients with impaired hepatic function.

  • HOW SUPPLIED

    Cefprozil Tablets USP

    Each white film-coated, capsule shaped tablet, debossed with "W712" on one side and plain on other side, contains the equivalent of 250 mg anhydrous cefprozil.

    Bottles of 50 Tablets                                 NDC 64679-712-01

    Bottles of 1000 Tablets                      NDC 64679-712-02

    Bottles of 100 Tablets                                 NDC 64679-712-03

    Bottles of 500 Tablets                                 NDC 64679-712-04

    Each white film-coated, capsule shaped tablet, debossed with "W713" on one side and plain on other side, contains the equivalent of 500 mg anhydrous cefprozil.

    Bottles of 50 Tablets                                 NDC 64679-713-01

    Bottles of 500 Tablets                                 NDC 64679-713-02

    Bottles of 100 Tablets                                 NDC 64679-713-03

    Store between 20° and 25°C (68° and 77°F) [See USP Controlled Room Temperature].

  • CLINICAL STUDIES

    Study One:

    In a controlled clinical study of acute otitis media performed in the United States where significant rates of β-lactamase-producing organisms were found, cefprozil was compared to an oral antimicrobial agent that contained a specific β-lactamase inhibitor. In this study, using very strict evaluability criteria and microbiologic and clinical response criteria at the 10 to 16 days post-therapy follow-up, the following presumptive bacterial eradication/clinical cure outcomes (i.e., clinical success) and safety results were obtained:

    U.S. Acute Otitis Media Study

    Cefprozil vs β-lactamase inhibitor-containing control drug

    EFFICACY:

    Pathogen
    % of Cases with Pathogen
    (n=155)
    Outcome
    S. pneumoniae
    48.4%
    cefprozil success rate 5% better than control
    H. influenzae
    35.5%
    cefprozil success rate 17% less than control
    M. catarrhalis
    13.5%
    cefprozil success rate 12% less than control
    S. pyogenes
    2.6%
    cefprozil equivalent to control
    Overall
    100%
    cefprozil success rate 5% less than control

    SAFETY:

    The incidences of adverse events, primarily diarrhea and rash*, were clinically and statistically significantly higher in the control arm versus the cefprozil arm.

    *The majority of these involved the diaper area in young children.

    Age Group
    Cefprozil
    Control
    6 months to 2 years
    21%
    41%
    3 to 12 years
    10%
    19%

    Study Two:

    In a controlled clinical study of acute otitis media performed in Europe, cefprozil was compared to an oral antimicrobial agent that contained a specific β-lactamase inhibitor. As expected in a European population, this study population had a lower incidence of β- lactamase-producing organisms than usually seen in U.S. trials. In this study, using very strict evaluability criteria and microbiologic and clinical response criteria at the 10-16 days post-therapy follow-up, the following presumptive bacterial eradication/clinical cure outcomes (i.e., clinical success) were obtained:

    European Acute Otitis Media Study

    Cefprozil vs β-lactamase inhibitor-containing control drug

    EFFICACY:

    Pathogen
    % of Cases with Pathogen
    (n=47)
    Outcome
    S. pneumoniae
    51 %
    cefprozil equivalent to control
    H. influenzae
    29.8 %
    cefprozil equivalent to control
    M. catarrhalis
    6.4 %
    cefprozil equivalent to control
    S. pyogenes
    12.8 %
    cefprozil equivalent to control
    Overall
    100 %
    cefprozil equivalent to control

    SAFETY:

    The incidence of adverse events in the cefprozil arm was comparable to the incidence of adverse events in the control arm (agent that contained a specific β-lactamase inhibitor).

    Manufactured by:

    Wockhardt Limited

    Plot No.B-15/2, M.I.D.C. Area, Waluj,

    Aurangabad, Maharashtra,

    India.

    Distributed by:

    Wockhardt USA LLC.

    20 Waterview Blvd.

    Parsippany, NJ 07054

    USA.

    Rev.020518

  • PRINCIPAL DISPLAY PANEL

    DRUG: Cefprozil

    GENERIC: Cefprozil

    DOSAGE: Film-coated Tablets

    ADMINSTRATION: Oral

    NDC: 64679-712-01

    STRENGTH: 250 mg

    SHAPE: Capsule

    IMPRINT: W 712

    QTY: 50 Tablets Bottle Label

    Label-250mg-50T

    DRUG: Cefprozil

    GENERIC: Cefprozil

    DOSAGE: Film-coated Tablets

    ADMINSTRATION: Oral

    NDC: 64679-713-01

    STRENGTH: 500 mg

    SHAPE: Capsule

    IMPRINT: W 713

    QTY: 50 Tablets Bottle Label

    Label-500mg-50T
  • INGREDIENTS AND APPEARANCE
    CEFPROZIL 
    cefprozil tablet, film coated
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:64679-712
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    CEFPROZIL (UNII: 4W0459ZA4V) (CEFPROZIL ANHYDROUS - UNII:1M698F4H4E) CEFPROZIL ANHYDROUS250 mg
    Inactive Ingredients
    Ingredient NameStrength
    CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)  
    HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED (UNII: 2165RE0K14)  
    HYPROMELLOSE 2910 (5 MPA.S) (UNII: R75537T0T4)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    METHYLCELLULOSE (15 CPS) (UNII: NPU9M2E6L8)  
    POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ)  
    SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)  
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
    Product Characteristics
    ColorWHITEScoreno score
    ShapeCAPSULESize14mm
    FlavorImprint Code W712
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:64679-712-0150 in 1 BOTTLE; Type 0: Not a Combination Product06/15/2007
    2NDC:64679-712-03100 in 1 BOTTLE; Type 0: Not a Combination Product06/15/2007
    3NDC:64679-712-04500 in 1 BOTTLE; Type 0: Not a Combination Product06/15/2007
    4NDC:64679-712-021000 in 1 BOTTLE; Type 0: Not a Combination Product06/15/2007
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA06542806/15/2007
    CEFPROZIL 
    cefprozil tablet, film coated
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:64679-713
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    CEFPROZIL (UNII: 4W0459ZA4V) (CEFPROZIL ANHYDROUS - UNII:1M698F4H4E) CEFPROZIL ANHYDROUS500 mg
    Inactive Ingredients
    Ingredient NameStrength
    CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)  
    HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED (UNII: 2165RE0K14)  
    HYPROMELLOSE 2910 (5 MPA.S) (UNII: R75537T0T4)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    METHYLCELLULOSE (15 CPS) (UNII: NPU9M2E6L8)  
    POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ)  
    SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)  
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
    Product Characteristics
    ColorWHITEScoreno score
    ShapeCAPSULESize19mm
    FlavorImprint Code W713
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:64679-713-0150 in 1 BOTTLE; Type 0: Not a Combination Product06/15/2007
    2NDC:64679-713-03100 in 1 BOTTLE; Type 0: Not a Combination Product06/15/2007
    3NDC:64679-713-02500 in 1 BOTTLE; Type 0: Not a Combination Product06/15/2007
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA06542806/15/2007
    Labeler - Wockhardt USA LLC. (170508365)
    Registrant - Wockhardt USA LLC. (170508365)
    Establishment
    NameAddressID/FEIBusiness Operations
    Wockhardt Limited915122332ANALYSIS(64679-712, 64679-713) , LABEL(64679-712, 64679-713) , MANUFACTURE(64679-712, 64679-713) , PACK(64679-712, 64679-713)